“Adalimumab treatment” improves dermatology-specific and general health-related quality of life (HRQoL), as well as reducing work and activity limitations and psoriasis-related symptoms in moderate to severe psoriasis patients.

These are the conclusive findings of a study recently taken place under the leadership of Dennis Revicki from the ‘United BioSource Corporation’. This study involved in the initial 16-week period of a double-blind, 52-week, Phase III, multicenter trial. Findings of this study and the conclusions have been recently published in the journal “Journal of Dermatological Treatment”.

Dennis Revicki, from the “United BioSource Corporation in Bethesda, Maryland, USA” and his researcher’s team randomly assigned 1205 patients with moderate to severe psoriasis to ‘adalimumab’ 80 mg or placebo at week 0 and ‘adalimumab’ 40 mg or placebo every other week from week 1 to week 15.

According to the details of the findings of the study, in comparison with patients treated with placebo, those given ‘adalimumab’ had significant improvements in “Dermatology Life Quality Index (DLQI)” total scores, Short Form 36 Health Survey (SF-36) Physical Component Summary scores, and Mental Component Summary scores.

In addition to this , the researchers also observed that the ‘adalimumab-treated patients’ showed significant improvements on the DLQI subscale scores, the SF-36 scale scores, the ‘Work Productivity and Activity Impairment Questionnaire-Specific Health Problem work impairment’, activity limitation, and overall work impairment scores.

Patients given ‘adalimumab’ also had significant improvements on the patient’s global assessment of disease severity, psoriasis pain scores, and psoriasis-related pruritis compared with placebo-treated patients, the researchers reported in the “Journal of Dermatological Treatment”.

Dennis Revicki concluded in the study report,”These results were considered clinically significant and are consistent with the clinical efficacy results of ‘adalimumab’ in this study. The HRQoL findings demonstrate the broad impact of alleviating the clinical symptoms of psoriasis on disease-related limitations, physical functioning and well-being, and psychological well-being”.